Nebenwirkungen · Accofil
Accofil 30 MU/0.5 ml solution for injection/infusion in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 14
HOS-221941 · Präparat HOS-216908
Hypersensitivity Hypersensitivity-type reactions including anaphylaxis, rash, urticaria, angioedema, dyspnoea and hypotension occurring on initial or subsequent treatment have been reported in clinical studies and in post-marketing experience. Overall, reports were more common after IV administration. In some cases, symptoms have recurred with rechallenge, suggesting a causal relationship. Filgrastim should be permanently discontinued in patients who experience a serious allergic reaction.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-25T15:11:00Z · SHA-256 c3518f7b95bc3dd24963f91afa5cd0272badfcd4a5f8943510b2f417086a82ed · Passage 433596d00960e3a9f5fec5157dff4bbeb748d2036bcb925403d9b3996b707769 · Zeichen 10346–10840 im Abschnitt